» Articles » PMID: 16684001

Genetic Diagnosis of Haemophilia and Other Inherited Bleeding Disorders

Overview
Journal Haemophilia
Specialty Hematology
Date 2006 May 11
PMID 16684001
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Inherited deficiencies of plasma proteins involved in blood coagulation generally lead to lifelong bleeding disorders, whose severity is inversely proportional to the degree of factor deficiency. Haemophilia A and B, inherited as X-linked recessive traits, are the most common hereditary hemorrhagic disorders caused by a deficiency or dysfunction of blood coagulation factor VIII (FVIII) and factor IX (FIX). Together with von Willebrand's disease, a defect of primary haemostasis, these X-linked disorders include 95% to 97% of all the inherited deficiencies of coagulation factors. The remaining defects, generally transmitted as autosomal recessive traits, are rare with prevalence of the presumably homozygous forms in the general population of 1:500,000 for FVII deficiency and 1 in 2 million for prothrombin (FII) and factor XIII (FXIII) deficiency. Molecular characterization, carrier detection and prenatal diagnosis remain the key steps for the prevention of the birth of children affected by coagulation disorders in developing countries, where patients with these deficiencies rarely live beyond childhood and where management is still largely inadequate. These characterizations are possible by direct or indirect genetic analysis of genes involved in these diseases, and the choice of the strategy depends on the effective available budget and facilities to achieve a large benefit. In countries with more advanced molecular facilities and higher budget resources, the most appropriate choice in general is a direct strategy for mutation detection. However, in countries with limited facilities and low budget resources, carrier detection and prenatal diagnosis are usually performed by linkage analysis with genetic markers. This article reviews the genetic diagnosis of haemophilia, genetics and inhibitor development, genetics of von Willebrand's disease and of rare bleeding disorders.

Citing Articles

Genomic Landscape of Chromosome X Factor VIII: From Hemophilia A in Males to Risk Variants in Females.

Morris O, Morris M, Jobe S, Bhargava D, Krueger J, Arora S Genes (Basel). 2025; 15(12.

PMID: 39766791 PMC: 11675246. DOI: 10.3390/genes15121522.


Long-term correction of hemophilia A via integration of a functionally enhanced FVIII gene into the AAVS1 locus by nickase in patient-derived iPSCs.

Kim D, Choi S, Sung J, Kim S, Yi H, Park S Exp Mol Med. 2025; 57(1):184-192.

PMID: 39762408 PMC: 11799516. DOI: 10.1038/s12276-024-01375-z.


Biomarkers Involved in the Pathogenesis of Hemophilic Arthropathy.

Badulescu O, Scripcariu D, Badescu M, Ciocoiu M, Vladeanu M, Plesoianu C Int J Mol Sci. 2024; 25(18).

PMID: 39337384 PMC: 11432147. DOI: 10.3390/ijms25189897.


Exploring the relationship between condition severity and health-related quality of life in people with haemophilia A across Europe: a multivariable analysis of data from the CHESS II study.

Ferri Grazzi E, Hawes C, Camp C, Hinds D, OHara J, Burke T Health Qual Life Outcomes. 2024; 22(1):58.

PMID: 39075533 PMC: 11288067. DOI: 10.1186/s12955-024-02267-6.


Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance).

Patel J, Jiang C, Owzar K, Hertz D, Wang J, Mulkey F Pharmacogenomics J. 2024; 24(2):6.

PMID: 38438359 PMC: 10912014. DOI: 10.1038/s41397-024-00328-z.